Related Experiment Video
Updated: May 15, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Uric acid and prognosis in angiography-proven coronary artery disease
Gjin Ndrepepa1, Siegmund Braun, Lamin King
1Deutsches Herzzentrum, Technische Universität, Munich, Germany. ndrepepa@dhm.mhn.de
Insights
High uric acid (UA) levels increase cardiac mortality risk in coronary artery disease (CAD) patients. The lowest mortality risk is observed with UA levels between 5.17 and 6.76 mg/dL, showing a J-shaped association.
Area of Science:
- Cardiology
- Biochemistry
- Public Health
Background:
- Optimal uric acid (UA) levels for predicting mortality in coronary artery disease (CAD) patients are not well-established.
- The association between UA and mortality across different patient subgroups requires further investigation.
Purpose of the Study:
- To determine the optimal uric acid (UA) level associated with the lowest mortality in patients with coronary artery disease (CAD).
- To evaluate the strength of association between UA levels and mortality in various CAD patient subgroups.
Main Methods:
- Analysis of 13,273 patients with confirmed CAD and available UA measurements.
- Primary outcome was 1-year mortality, with ROC curve analysis to identify optimal UA cut-off for prediction.
Main Results:
- A UA level of 7.11 mg/dL was the optimal cut-off for mortality prediction.
- Patients with UA > 7.11 mg/dL had significantly higher cardiac mortality (6.3%) compared to those with UA ≤ 7.11 mg/dL (2.3%).
- UA remained an independent predictor of cardiac mortality, with a J-shaped relationship observed, indicating lowest mortality between 5.17 and 6.76 mg/dL.
Conclusions:
- Uric acid (UA) predicts increased cardiac mortality risk in all coronary artery disease (CAD) patient subgroups.
- The association between UA and mortality follows a J-shaped pattern, with the lowest risk observed at UA levels between 5.17 and 6.76 mg/dL.
Background:
The optimal uric acid (UA) level associated with the lowest mortality and the strength of association between UA and mortality in various subgroups of patients with coronary artery disease (CAD) are unknown.
Materials And Methods:
This study included 13 273 patients with angiographic confirmation of CAD and UA measurements available. The primary outcome analysis was 1-year mortality.
Results:
Based on the receiver operating characteristic curve analysis, the best cut-off of UA for mortality prediction was 7·11 mg/dL. Using this cut-off, patients were divided into two groups: the group with UA ≤ 7·11 mg/dL (n = 9075) and the group with UA > 7·11 mg/dL (n = 4198). Cardiac mortality was 6·3% (256 deaths) in patients with UA > 7·11 mg/dL and 2·3% (201 deaths) in patients with UA ≤ 7·11 mg/dL [hazard ratio (HR) = 2·82, 95% confidence interval (CI) 2·36-3·36; P < 0·001]. After adjustment for cardiovascular risk factors, UA remained an independent correlate of cardiac mortality (HR = 1·20, 95% CI 1·08-1·34; P = 0·001, for each standard deviation increase in the logarithmic scale of UA). The relationship between cardiac or all-cause mortality and UA showed a J-shaped pattern with lowest mortality in patients with UA between 5·17 and 6·76 mg/dL. UA predicted mortality across all subgroups of patients, with strongest association in women and patients without arterial hypertension.
Conclusions:
UA predicted an increased risk of cardiac mortality across all subgroups of patients with CAD. The association between UA and cardiac or all-cause mortality had a 'J-shaped' pattern with lowest risk of death in patients with UA levels between 5·17 and < 6·76 mg/dL.
More Related Videos
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Imaging Studies V: Intravenous Urography and Retrograde Pyelography
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Coronary Artery Disease V: Interprofessional Care

